MP
CPRX

Mangrove Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Mangrove Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,031,965
Closed -$9.01M – 104
2020
Q3 		$9.01M Sell
3,031,965
-98,230
-3% -$384K 1.14% 25
2020
Q2 		$14.5M Sell
3,130,195
-1,225,221
-28% -$5.51M 3.53% 9
2020
Q1 		$16.8M Buy
4,355,416
+2,807,100
+181% +$11.5M 2.31% 14
2019
Q4 		$5.81M Sell
1,548,316
-960,522
-38% -$4.49M 0.85% 27
2019
Q3 		$13.3M Sell
2,508,838
-1,328,343
-35% -$7.08M 1.61% 21
2019
Q2 		$14.7M Buy
3,837,181
+380,140
+11% +$1.64M 1.67% 18
2019
Q1 		$17.6M Buy
3,457,041
+1,088,711
+46% +$3.2M 2.36% 15
2018
Q4 		$4.55M Buy
2,368,330
+690,386
+41% +$1.98M 0.61% 35
2018
Q3 		$6.34M Hold
1,677,944
– – 0.4% 25
2018
Q2 		$5.24M Buy
1,677,944
+169,635
+11% +$515K 0.34% 25
2018
Q1 		$3.6M Buy
1,508,309
+583,661
+63% +$1.94M 0.23% 29
2017
Q4 		$3.62M Buy
+924,648
New +$3.05M 0.49% 26

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Mangrove Partners's CPRX Position: Q4 2020 in Review

Mangrove Partners sold out of Catalyst Pharmaceutical (CPRX) in Q4 2020, closing a stake of 3,031,965 shares — an estimated $9.01M sold.

Mangrove Partners first reported a position in CPRX in Q4 2017 and held it in 12 quarters. The position peaked at $17.6M in Q1 2019. 135 funds tracked by Wall St. Rank hold CPRX as of Q4 2020.

  • Mangrove Partners reported no remaining Catalyst Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Mangrove Partners sold 3,031,965 Catalyst Pharmaceutical shares in Q4 2020, an estimated $9.01M.
  • Mangrove Partners first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 12 quarters.
  • Mangrove Partners's Catalyst Pharmaceutical position peaked at $17.6M in Q1 2019.
  • 135 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2020.

Based on Mangrove Partners's 13F filing for Q4 2020, filed 16 Feb 2021.